FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801463953> ?p ?o ?g. }

• W2801463953 endingPage "1406" @default.
• W2801463953 startingPage "1397" @default.
• W2801463953 abstract "Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532). Herein, we report the study extension evaluating 24 months of treatment with romosozumab, discontinuation of romosozumab, alendronate followed by romosozumab, and romosozumab followed by denosumab. Postmenopausal women aged 55 to 85 years with a lumbar spine (LS), total hip (TH), or femoral neck T-score ≤-2.0 and ≥-3.5 were enrolled and randomly assigned to placebo, one of five romosozumab regimens (70 mg, 140 mg, 210 mg monthly [QM]; 140 mg Q3M; 210 mg Q3M) for 24 months, or open-label alendronate for 12 months followed by romosozumab 140 mg QM for 12 months. Eligible participants were then rerandomized 1:1 within original treatment groups to placebo or denosumab 60 mg Q6M for an additional 12 months. Percentage change from baseline in BMD and bone turnover markers (BTMs) at months 24 and 36 and safety were evaluated. Of 364 participants initially randomized to romosozumab, placebo, or alendronate, 315 completed 24 months of treatment and 248 completed the extension. Romosozumab markedly increased LS and TH BMD through month 24, with largest gains observed with romosozumab 210 mg QM (LS = 15.1%; TH = 5.4%). Women receiving romosozumab who transitioned to denosumab continued to accrue BMD, whereas BMD returned toward pretreatment levels with placebo. With romosozumab 210 mg QM, bone formation marker P1NP initially increased after treatment initiation and gradually decreased to below baseline by month 12, remaining below baseline through month 24; bone resorption marker β-CTX rapidly decreased after treatment, remaining below baseline through month 24. Transition to denosumab further decreased both BTMs, whereas after transition to placebo, P1NP returned to baseline and β-CTX increased above baseline. Adverse events were balanced between treatment groups through month 36. These data suggest that treatment effects of romosozumab are reversible upon discontinuation and further augmented by denosumab. © 2018 The Authors Journal of Bone and Mineral Research published by Wiley Periodicals, Inc." @default.
• W2801463953 created "2018-05-17" @default.
• W2801463953 creator A5008203290 @default.
• W2801463953 creator A5009121071 @default.
• W2801463953 creator A5010429279 @default.
• W2801463953 creator A5011600720 @default.
• W2801463953 creator A5023121519 @default.
• W2801463953 creator A5032907896 @default.
• W2801463953 creator A5045290077 @default.
• W2801463953 creator A5046513778 @default.
• W2801463953 creator A5049544471 @default.
• W2801463953 creator A5052312125 @default.
• W2801463953 creator A5063460033 @default.
• W2801463953 creator A5090611203 @default.
• W2801463953 creator A5091056303 @default.
• W2801463953 date "2018-05-22" @default.
• W2801463953 modified "2023-10-06" @default.
• W2801463953 title "Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study" @default.
• W2801463953 cites W1030819271 @default.
• W2801463953 cites W1911703092 @default.
• W2801463953 cites W1983220846 @default.
• W2801463953 cites W2021829493 @default.
• W2801463953 cites W2032956576 @default.
• W2801463953 cites W2045787805 @default.
• W2801463953 cites W2060336303 @default.
• W2801463953 cites W2081887629 @default.
• W2801463953 cites W2096627331 @default.
• W2801463953 cites W2108403721 @default.
• W2801463953 cites W2123511777 @default.
• W2801463953 cites W2134910437 @default.
• W2801463953 cites W2138023846 @default.
• W2801463953 cites W2520995084 @default.
• W2801463953 cites W2738136796 @default.
• W2801463953 cites W2754720807 @default.
• W2801463953 cites W2766957057 @default.
• W2801463953 cites W2791948389 @default.
• W2801463953 doi "https://doi.org/10.1002/jbmr.3452" @default.
• W2801463953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29694685" @default.
• W2801463953 hasPublicationYear "2018" @default.
• W2801463953 type Work @default.
• W2801463953 sameAs 2801463953 @default.
• W2801463953 citedByCount "129" @default.
• W2801463953 countsByYear W28014639532018 @default.
• W2801463953 countsByYear W28014639532019 @default.
• W2801463953 countsByYear W28014639532020 @default.
• W2801463953 countsByYear W28014639532021 @default.
• W2801463953 countsByYear W28014639532022 @default.
• W2801463953 countsByYear W28014639532023 @default.
• W2801463953 crossrefType "journal-article" @default.
• W2801463953 hasAuthorship W2801463953A5008203290 @default.
• W2801463953 hasAuthorship W2801463953A5009121071 @default.
• W2801463953 hasAuthorship W2801463953A5010429279 @default.
• W2801463953 hasAuthorship W2801463953A5011600720 @default.
• W2801463953 hasAuthorship W2801463953A5023121519 @default.
• W2801463953 hasAuthorship W2801463953A5032907896 @default.
• W2801463953 hasAuthorship W2801463953A5045290077 @default.
• W2801463953 hasAuthorship W2801463953A5046513778 @default.
• W2801463953 hasAuthorship W2801463953A5049544471 @default.
• W2801463953 hasAuthorship W2801463953A5052312125 @default.
• W2801463953 hasAuthorship W2801463953A5063460033 @default.
• W2801463953 hasAuthorship W2801463953A5090611203 @default.
• W2801463953 hasAuthorship W2801463953A5091056303 @default.
• W2801463953 hasBestOaLocation W28014639531 @default.
• W2801463953 hasConcept C126322002 @default.
• W2801463953 hasConcept C142724271 @default.
• W2801463953 hasConcept C170033053 @default.
• W2801463953 hasConcept C204787440 @default.
• W2801463953 hasConcept C27081682 @default.
• W2801463953 hasConcept C2775854910 @default.
• W2801463953 hasConcept C2776286101 @default.
• W2801463953 hasConcept C2776541429 @default.
• W2801463953 hasConcept C2776886416 @default.
• W2801463953 hasConcept C71924100 @default.
• W2801463953 hasConceptScore W2801463953C126322002 @default.
• W2801463953 hasConceptScore W2801463953C142724271 @default.
• W2801463953 hasConceptScore W2801463953C170033053 @default.
• W2801463953 hasConceptScore W2801463953C204787440 @default.
• W2801463953 hasConceptScore W2801463953C27081682 @default.
• W2801463953 hasConceptScore W2801463953C2775854910 @default.
• W2801463953 hasConceptScore W2801463953C2776286101 @default.
• W2801463953 hasConceptScore W2801463953C2776541429 @default.
• W2801463953 hasConceptScore W2801463953C2776886416 @default.
• W2801463953 hasConceptScore W2801463953C71924100 @default.
• W2801463953 hasIssue "8" @default.
• W2801463953 hasLocation W28014639531 @default.
• W2801463953 hasLocation W28014639532 @default.
• W2801463953 hasLocation W28014639533 @default.
• W2801463953 hasLocation W28014639534 @default.
• W2801463953 hasOpenAccess W2801463953 @default.
• W2801463953 hasPrimaryLocation W28014639531 @default.
• W2801463953 hasRelatedWork W1909034630 @default.
• W2801463953 hasRelatedWork W2009819071 @default.
• W2801463953 hasRelatedWork W2054660180 @default.
• W2801463953 hasRelatedWork W2116817852 @default.
• W2801463953 hasRelatedWork W2355521031 @default.
• W2801463953 hasRelatedWork W2382488356 @default.
• W2801463953 hasRelatedWork W2492519731 @default.
• W2801463953 hasRelatedWork W2981000976 @default.

• next